1. (valid email required)
 

cforms contact form by delicious:days

Archive for August, 2010

Maestro™ for kinetic imaging to be announced at Workshop at WMIC in Kyoto

CRi will announce and demonstrate a new Maestro™ System for in vivo kinetic imaging at a September 7 workshop in Kyoto at the World Molecular Imaging Congress.

Woburn, Massachusetts – August 4, 2010- CRi will announce and demonstrate a new Maestro™ system for in vivo kinetic imaging at a Workshop in Kyoto at the World Molecular Imaging Congress. Leading researchers will discuss how they use their CRi Maestro™ In-Vivo Imaging Systems to investigate target identification, tumor tracking, antibody labeling and kinetic modeling. Discussions will also include helpful tips and tricks and updates regarding CRi’s latest system developments, including the availability of the new Maestro system with included DyCE™ (Dynamic Contrast Enhancement) technology that generates time-based images and movies of fluorescent reagents and labeled antibodies, providing quantitative data on the temporal biodistribution of fluorescent markers at much earlier time points than is possible using conventional imaging methods, and enabling better discrimination between bound and unbound antibodies.

Featured speakers at the workshop include:

– Hisataka Kobayashi, Staff Scientist, NIH Molecular Imaging Program

– Yasuteru Urano, University of Tokyo

– Zhuang Liu, Soochow University

– James R. Mansfield, Director, Multispectral Imaging Systems, CRi

Workshop details:

– Tuesday, September 7, 2010 (Day before the WMIC conference begins)

– 2:00 pm to 5:30 pm

– Room K, International Conference Center, Kyoto, Japan

Refreshments and hors d’oeuvres will be provided and seating is limited.

Sign Up Now.

Maestro™ for kinetic imaging to be announced at Workshop at WMIC in Kyoto
Woburn, Massachusetts - August 4, 2010- CRi will announce and demonstrate a new Maestro™ system for in vivo kinetic imaging at a Workshop in Kyoto at the World Molecular Imaging Congress. Leading researchers will discuss how they use their CRi Maestro™ In-Vivo Imaging Systems to investigate target identification, tumor tracking, antibody labeling and kinetic modeling. »

GlaxoSmithKline, AstraZeneca and other Pharmaceutical Leaders Reduce R&D Time and Costs Using AspenTech’s Software

Industry Collaboration Results in Newly Patented Technology that Helps Drug Companies Comply with Latest Regulatory “Quality by Design” Initiatives

Burlington, Mass – July19th, 2010- Aspen Technology, Inc. (NASDAQ: AZPN), a leading provider of software and services to the process industries, today announced that GlaxoSmithKline, AstraZeneca and other pharmaceutical industry leaders are reducing their research and development time and costs using newly patented technology that is part of AspenTech’saspenONE Process Development for Pharmaceuticals software.

Supporting Quotes:
Stephen Carino, Investigator – Solid Form Sciences Group, GlaxoSmithKline
“Screening for crystalline forms is an essential component in pharmaceutical drug development. In our high-throughput screening workflow, we have utilized NRTL-SAC in Aspen Properties to predict the equilibrium solubility of the drug in single- and multi-component solvent systems. The predicted solubility values are used in selecting an appropriate set of solvent systems that are explicitly unique for each of the crystallization modes. This rational solvent selection coupled with the systematic screening approach has allowed us to assess risk around solid forms and improve our confidence in the robustness of the API processes.”

Jamie Hintlian, Vice President of Pharmaceuticals, Aspen Technology, Inc.
“Solubility is essential in evaluating drug candidacy and manufacturability. Without predictive tools, many organizations are forced to fly blind when it comes to this mission-critical information. Solubility modeling and prediction adds value by enabling greater efficiencies, better decision making, faster process development, and better process performance. For the pharmaceutical industry leaders involved in its development, and other potential users, this is a powerful screening protocol for the drug development process.”

Supporting Resources:

About AspenTech
AspenTech is a leading supplier of software that optimizes process manufacturing – for energy, chemicals, pharmaceuticals, engineering and construction, and other industries that manufacture and produce products from a chemical process. With integrated aspenONE solutions, process manufacturers can implement best practices for optimizing their engineering, manufacturing and supply chain operations. As a result, AspenTech customers are better able to increase capacity, improve margins, reduce costs and become more energy efficient. To see how the world’s leading process manufacturers rely on AspenTech to achieve their operational excellence goals, visit www.aspentech.com.

GlaxoSmithKline, AstraZeneca and other Pharmaceutical Leaders Reduce R&D Time and Costs Using AspenTech’s Software
Burlington, Mass - July19th, 2010- Aspen Technology, Inc. (NASDAQ: AZPN), a leading provider of software and services to the process industries, today announced that GlaxoSmithKline, AstraZeneca and other pharmaceutical industry leaders are reducing their research and development time and costs using newly patented technology that is part of AspenTech’saspenONE Process Development for Pharmaceuticals software. »

AspenTech Announces Availability of 7.2 Release of aspenONE V7

Building on aspenONE V7 Innovations and Best Practice Input from Users, 7.2 Release Makes Process Optimization Faster and Easier

Burlington, Mass – July 13, 2010 –Aspen Technology, Inc. (NASDAQ: AZPN), a leading provider of software and services to the process industries, today announced the availability of the 7.2 release of aspenONE software. Building on innovations delivered in aspenONE V7 and best practice input from users, the 7.2 release makes optimizing engineering, manufacturing and supply chain processes faster and easier. Examples include:

The new features are the latest in a series of innovations delivered by aspenONE V7, which sets the standard for best practices in process optimization. For information on these and many other new features and enhancements in the 7.2 release of aspenONE, visit http://www.aspentech.com/v7/v72_enhancements.cfm.

Supporting Quote
Manolis Kotzabasakis, Senior Vice President, Sales & Strategy, AspenTech
“Since its initial release in September 2008, over 1,000 AspenTech customers have deployed aspenONE V7 to help improve profitability and achieve operational excellence goals. The 7.2 release incorporates hundreds of best practice ideas from our customer base. Now, it’s easier than ever for process industry companies to optimize engineering, manufacturing and supply chain processes for greater profitability.”

Supporting Resources

About AspenTech
AspenTech is a leading supplier of software that optimizes process manufacturing – including energy, chemicals, pharmaceuticals, engineering & construction, power & utilities and other industries that manufacture and produce products from a chemical process. With integrated aspenONE solutions, process manufacturers can implement best practices for optimizing their engineering, manufacturing and supply chain operations. As a result, AspenTech customers are better able to increase capacity, improve margins, reduce costs and become more energy efficient. To see how the world’s leading process manufacturers rely on AspenTech to achieve their operational excellence goals, visit www.aspentech.com.

AspenTech Announces Availability of 7.2 Release of aspenONE V7
Burlington, Mass - July 13, 2010 -Aspen Technology, Inc. (NASDAQ: AZPN), a leading provider of software and services to the process industries, today announced the availability of the 7.2 release of aspenONE software. Building on innovations delivered in aspenONE V7 and best practice input from users, the 7.2 release makes optimizing engineering, manufacturing and supply chain processes faster and easier. »

July 2010 Newsletter

Mass. Capital is pleased to announce that its portfolio company Innov-X Systems Inc. was acquired by Olympus NDT, a world leader in nondestructive testing (NDT) and related inspection technologies, on July 2, 2010.  Innov-X is a leading manufacturer of portable X-ray fluorescence (XRF) analytical instruments based in Woburn.  Innov-X Systems instruments provide real-time, nondestructive material analysis in applications ranging from metal sorting, lead paint detection, and alloy verification to analysis of oil, fluids, and minerals.  The addition of X-ray fluorescence analytical instruments augments Olympus NDT’s existing portfolio of ultrasound, eddy current, and remote visual instruments that include flaw detectors, thickness gages, systems, videoscopes, scanners, probes, and related accessories.   Innov-X Systems, Inc. will be operated as a business division of Olympus NDT, retaining its current management team and employee base.

Innov-X Systems C.E.O. Don Sackett commented:  “We are extremely honored to be part of the Olympus organization, which is so well respected throughout the world.  Innov-X has newly introduced an X-ray fluorescence product platform that is both high performance and rugged and is a great fit with the nondestructive testing and remote visual inspection technologies of Olympus.  I look forward to the synergies and opportunities to extend our technological leadership and quality created by the joining of these two companies.”

For more information on Innov-X Systems, please visit www.innovx.com.

innovx

July 2010 Newsletter
Mass. Capital is pleased to announce that its portfolio company Innov-X Systems Inc. was acquired by Olympus NDT, a world leader in nondestructive testing (NDT) and related inspection technologies, on July 2, 2010.  Innov-X is a leading manufacturer of portable X-ray fluorescence (XRF) analytical instruments based in Woburn.  Innov-X Systems instruments provide real-time, nondestructive material […] »

CRi Names Darren Lee Vice President of Marketing

New position reflects CRi’s continued growth in 2010.

Woburn, Massachusetts June 22, 2010 –

masscapmugshot

Cambridge Research & Instrumentation, Inc. (CRi), a leader in pre-clinical and molecular imaging, today announced the appointment of Darren Lee as the company’s vice president of marketing. He will be responsible for leading all strategic marketing activities for the company’s products and sales across the United States and worldwide.

“CRi’s technology is positioned to lead the emerging field of tissue-based multiplexed analysis from basic research through diagnostics,” said Lee. “I’m excited about the opportunity to help drive growth in these key segments, further enabling our customers to more rapidly identify and validate biomarkers of disease, leading to new therapeutics and companion diagnostics.”

Lee comes to CRi with more than 20 years of experience in marketing management, business development and engineering in the life sciences and clinical diagnostics industries.

“Darren’s extensive experience and proven leadership in the field of biotechnology will be a tremendous asset,” said George Abe, president and chief executive officer of CRi. “We are excited to add him to our management team and believe his expertise will contribute greatly to the continued development of the company.”

Lee has held senior-level management positions at Primera Biosystems, a molecular diagnostics company, and Decision Biomarkers, a life-science systems developer. He has also served in senior management positions at PerkinElmer and Packard Bioscience. He has a B.S. in Biomedical Engineering Technology from Temple University and an M.S. in Technology Management from Pepperdine University.

About CRi, Inc.

Cambridge Research & Instrumentation, Inc. (CRi) develops and markets optical imaging systems to advance biomedical research and molecular-based drug and diagnostic development. CRi’s patented systems enable researchers and clinicians to quantitate multiple disease and drug response markers in intact tissue samples, at a cellular level or in living small animals. CRi’s products integrate a unique multispectral imaging technology with proprietary image analysis algorithms to achieve unparalleled accuracy and sensitivity, rapidly and cost-effectively. CRi’s award-winning systems include Nuance™ for multispectral imaging on brightfield and fluorescence microscopes; inForm™ automated image analysis software; Vectra™ for high-throughput slide imaging and analysis; and Maestro™ for in-vivo optical imaging. Learn more at www.cri-inc.com.

For more information, contact:

Cambridge Research & Instrumentation, Inc. (CRi)

Cathy Boutin

781-935-9099

Marketing Manager

cboutin@cri-inc.com

Commonwealth Creative Associates

Jamie Bull

508-620-0791

Digital Media Strategist

jamieb@commcreative.com

Commonwealth Creative Associates

Donna Phelps

508-620-0791

Senior Account Executive

donnap@commcreative.com

CRi Names Darren Lee Vice President of Marketing
Woburn, Massachusetts June 22, 2010 - Cambridge Research & Instrumentation, Inc. (CRi), a leader in pre-clinical and molecular imaging, today announced the appointment of Darren Lee as the company’s vice president of marketing. He will be responsible for leading all strategic marketing activities for the company’s products and sales across the United States and worldwide. »

Riverside Health System Benefits from New Model of Care Facilitation Powered by Curaspan Health Group

Award-Winning Software-as-a-Service Application Generates Clinical, Business Results for IDN

Newton, Mass. June 16, 2010 — Curaspan Health Group, the industry leader in building secure electronic patient-transition networks for hospitals, post-acute providers and suppliers, has helped Riverside Health System (RHS) dramatically increase referrals within its network. In one year, in-network patient placements jumped from 30% to 60%.

Serving the communities of Southeastern Virginia with an integrated delivery network of hospitals, surgery centers, retirement communities, assisted-living facilities, long-term care facilities, physician practice locations and other services, RHS deployed the Curaspan eDischargeTM software-as-a-service (SaaS) application as its platform for enhancing communication, operations and care network-wide.

“We look across the system, at all the facilities, and we see the whole pie – not just one slice,” said Dawn Kowalski, operations manager for Riverside Health System. “We could not do this without Curaspan.” The RHS collaboration with Curaspan is detailed in a new case study, Riverside Health System Knocks Down IT Silos, Builds New Model of Care Facilitation.

“It’s the patient that counts, not a building,” added Melody Livengood, RN, MSN, director of care facilitation at RHS. “We’re looking at what’s best for the patient.”

Built with clinical expertise from case managers, discharge planners and social workers, Curaspan SaaS applications empower users with actionable data to help streamline the patient-transition process, improve the quality of care, and by extension, the bottom line.

“We’re very pleased that our partnership with Riverside is contributing to demonstrable benefits with quantifiable results for the system and its patients,” said Thomas R. Ferry, president and CEO of Curaspan.

Curaspan works with many of the nation’s top hospitals and post-acute care providers including Johns Hopkins Health System, New York Presbyterian, St. Thomas Health Services (part of Ascension Health), Vanguard Health Systems, Amedisys Home Health Services, American Medical Response, Gentiva Health Services, Golden LivingCenters, Kindred Healthcare, Life Care Centers of America and Sunbridge Health, among many others.

About Curaspan Health Group
Curaspan Health Group builds secure electronic patient-transition networks for hospitals, post-acute providers and suppliers to optimize patient care. Curaspan software-as-a-service (SaaS) applications empower users with real-time, predictive decision-making data that enables all participants to continuously monitor care, improve communication and ensure compliance. This informatics exchange is integrated with the proprietary Curaspan Provider Data Bank, the industry’s most comprehensive and up-to-date system of actionable patient-transition intelligence, and is complemented by the clinical process expertise of credentialed advisors. The Health Care Advisory Board and KLAS repeatedly have recognized Curaspan for its industry-leading software. Curaspan is headquartered in Newton, Mass. For more information please visit Curaspan.com.


Media Contact:

Sarah Mees
KMC Partners Public Relations
978-208-1499
Sarah@KMCPartners.com

Riverside Health System Benefits from New Model of Care Facilitation Powered by Curaspan Health Group
Newton, Mass. June 16, 2010 — Curaspan Health Group, the industry leader in building secure electronic patient-transition networks for hospitals, post-acute providers and suppliers, has helped Riverside Health System (RHS) dramatically increase referrals within its network. In one year, in-network patient placements jumped from 30% to 60%. »

Latest News

Datawatch Self-Service Data Preparation Platform in High Demand in Healthcare Market

NWN Recognized in CRN Elite 150 For Managed IT Services and Placed on Managed Service Provider 500 List

Bigbelly Unveils Top 2016 Successes for Optimized Collections & Recycling Diversion

Southern California Edison Awards Cadmus MSA to Support Zero Net Energy Schools

» More News


Latest Newsletters

April 2017 – MCRC Announces a New Investment in Baynes Electric Supply

March 2017 – Mass Capital Announces a New Investment in Tri-Wire Engineering Solutions, Inc.

July 2016 – Mass Capital Announces a New Investment in The Cadmus Group, Inc.

» More Newsletters


Archives!